Pasithea Therapeutics Corp. (NASDAQ: KTTA)

Pasithea Therapeutics Corp. is a clinical stage biotechnology company focused on the discovery research and development of innovative treatments for RASopathies MAPK pathway driven tumors and other diseases including central nervous system disorders.

Pasithea Therapeutics Corp. has not yet generated revenue from product sales as it remains in the clinical development stage. The company has recorded grant income from research agreements such as the FightMND grant which contributed forty three thousand dollars in 2025 and finances its operations through equity offerings and other capital raising activities.

Pasithea Therapeutics Corp. positions itself as a developer of next generation MEK inhibitors with a macrocyclic structure designed to improve safety and pharmacokinetic properties relative to existing FDA approved agents. Key competitors include AstraZeneca PLC which markets Koselugo Merck KGaA which markets Mektovi and other firms such as Pfizer Novartis and Roche that have approved MEK inhibitors for oncology indications. The company's lead candidate PAS 004 offers a longer half life lower peak to trough ratio and the potential for once daily dosing which may improve tolerability and patient adherence.

Pasithea Therapeutics Corp. intends to serve patients suffering from NF1 associated plexiform neurofibromas and other MAPK driven conditions. The company also targets individuals with solid tumors harboring BRAF mutations and patients with central nervous system disorders such as amyotrophic lateral sclerosis.